Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02834624 · ClinicalTrials.gov registry record · NA

Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome

A NA study, sponsored by University of Missouri-Columbia.

Completed
Registry status
NA
Development phase
30
Enrollment target

NCT02834624 is a NA study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02834624, a NA study, has completed, sponsored by University of Missouri-Columbia.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

Premature infants frequently have trouble breathing after birth. If the respiratory disorder is caused by surfactant deficiency or dysfunction, the disease is treated with a medication called surfactant that is given to the infant through a tube inserted into the windpipe. This study will compare the safety of two of the commonly used surfactants, poractant and calfactant,in the United States. Poractant has added chemicals called phospholipids which are known to cause inflammation and irritation in the body of premature infants. The investigators will compare this to another similar surfactant that does not contain these chemicals by looking at samples from the windpipe, while the tube is in place, and from blood tests in the first few days of life. The investigators are hoping to learn whether calfactant is a safer therapeutic agent to treat respiratory distress syndrome in preterm infants compared to poractant.

Interventions

  • DRUG Poractant alfa
  • DRUG calfactant

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2013-07
Est. Completion 2015-07
Phase NA

Sponsor

University of Missouri-Columbia

291 total trials

What the Registry Record Tells You About NCT02834624

The ClinicalTrials.gov registry entry for NCT02834624 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Poractant alfa is the first listed.

NCT02834624 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02834624 about?

NCT02834624 is a clinical study titled "Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome". Premature infants frequently have trouble breathing after birth. If the respiratory disorder is caused by surfactant deficiency or dysfunction, the disease is treated with a medication called surfactant that is given to the infant through a tube inserted into the windpipe. This study will compare th...

What is the current status of trial NCT02834624?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2013-07. Estimated completion is 2015-07.

What interventions are being tested in trial NCT02834624?

The interventions under investigation include: Poractant alfa (DRUG), calfactant (DRUG).

Who is sponsoring clinical trial NCT02834624?

This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.